Physician

Benjamin Bruce Freeman, M.D.

According to 2025 Medicare claims, Benjamin Freeman, M.D. (NPI: 1912206434) practices medical oncology in the Newark, NJ market, with the plurality of this provider's patient population coming from Essex, NJ. This provider's primary affiliated billing organization is BARNABAS HEALTH MEDICAL GROUP PC (NPI: 1841557246; TIN: 454832340) and primary practice location at 07039-5672. Freeman is affiliated with the RWJBH Accountable Care, LLC (ACO ID: A1247), Summit Health ACO (ACO ID: A5049), Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Freeman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 385 traditional Medicare patients, billed 4,712 HCPCS/CPT codes, and received $158,702 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,087 prescription claims across 199 beneficiaries totaling $3,269,261 in drug costs, led by Nubeqa (Darolutamide). 2018 DME data shows 15 claims. Open Payments data shows 45 records totaling $594,130. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $603,159 to $158,702. In contrast, Part D prescription costs have moved sharply higher in recent years, from $298,441 to $3,269,261. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	337	33,615	$603,159
2016	364	94,948	$1,222,371
2017	334	93,450	$1,157,225
2018	375	109,274	$1,397,281
2019	338	125,258	$1,685,825
2020	320	114,375	$1,395,727
2021	366	115,558	$995,315
2022	443	16,069	$361,563
2023	379	9,784	$194,206
2024	385	4,712	$158,702

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	54	258	$298,441
2016	77	393	$506,409
2017	80	418	$409,712
2018	97	576	$1,109,724
2019	128	862	$2,265,245
2020	134	898	$1,631,245
2021	166	1,002	$1,618,429
2022	187	1,084	$2,096,499
2023	188	1,042	$2,723,754
2024	199	1,087	$3,269,261

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	29	$10,662
2018	N/R	15	$3,916
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	149	336	$150
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	226	461	$103
80053	Blood test, comprehensive group of blood chemicals	196	359	$10
36415	Insertion of needle into vein for collection of blood sample	228	488	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	226	488	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nubeqa	Darolutamide	61	1,830	$811,339
Promacta	Eltrombopag Olamine	21	630	$350,949
Xtandi	Enzalutamide	22	660	$307,491
Abiraterone Acetate	Abiraterone Acetate	119	3,688	$233,199
Ninlaro	Ixazomib Citrate	12	336	$158,798

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$28	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	44	$594,103	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Benjamin Bruce Freeman, M.D.?

Tedicare shows public-source Medicare data for Benjamin Bruce Freeman, M.D. (NPI 1912206434), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Benjamin Bruce Freeman, M.D. have ACO affiliation data?

Benjamin Bruce Freeman, M.D. is shown with ACO affiliation data for RWJBH Accountable Care, LLC (MSSP, ACO ID A1247), Summit Health ACO (MSSP, ACO ID A5049), Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Benjamin Bruce Freeman, M.D.?

Benjamin Bruce Freeman, M.D. is linked to BARNABAS HEALTH MEDICAL GROUP PC (billing NPI 1841557246) in the available physician profile data.

Does Benjamin Bruce Freeman, M.D. have Open Payments data?

Benjamin Bruce Freeman, M.D. has 45 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.